中重度系统性红斑狼疮患者的泰它西普规范化治疗效果观察

Observation on the Effect of Standardized Treatment of Titacept for Patients with Moderate to Severe Systemic Lupus Erythematosus

目的:探究中重度系统性红斑狼疮患者不同剂量泰它西普规范化治疗后效果。方法:分析白银市第一人民医院风湿免疫科90例中重度系统性红斑狼疮患者(2022年1月—2023年12月),按照1:1:1原则随机分为3组。患者均给予遵照医护人员指导下规范用药剂量治疗方案,外加泰它西普皮下注射80 mg(观察1组)、160 mg(观察2组)以及240 mg(观察3组)治疗,对比分析泰它西普规范化治疗临床效果以及安全性。结果:规范化治疗后,观察1、2、3组临床治疗总有效率分别为90.00%、93.33%、86.67%(P>0.05);免疫学指标对比,观察2组补体C3、C4水平最高,免疫球蛋白IgG、IgM水平最低(P<0.05),免疫球蛋白IgA水平比较,无显著差异(P>0.05);三组治疗过程不良反应发生率比较,无显著差异(P>0.05)。结论:不同剂量泰它西普治疗中重度系统性红斑狼疮,临床治疗效果相差不大,治疗安全性未显著降低,免疫指标水平于注射剂量为160 mg时最优,可临床应用推广。

Objective:To explore the effect of different doses in patients with moderate to severe systemic lupus erythematosus.Methods:Ninety patients with moderate to severe systemic lupus erythematosus(from January 2022 to December 2023)were analyzed and randomly divided into three groups according to the principle of 1:1:1.The patients were treated under the guidance of medical staff,plus subcutaneous injection of 80 mg(observation group 1),160 mg(observation group 2)and 240 mg(observation group 3),and the clinical effect and safety of standardized treatment of titacept were analyzed.Results:After standardized treatment,the total response rate of groups 1,2 and 3 was 90.00%,93.33%and 86.67%(P>0.05);in terms of the immunological indexes,the group 2 had the highest complement C3 and C4 and the lowest immunoglobulin IgG and IgM(P<0.05);there was no significant difference in immunoglobulin IgA levels(P>0.05);there were no significant difference in terms of the incidence of adverse reactions in the three groups(P>0.05).Conclusion:In the treatment of moderate to severe systemic lupus erythematosus at different doses,the clinical treatment effect is not different,the treatment safety is not significantly reduced,and the immune index level is optimal when the injection dose is 160 mg,which can be applied in clinical application and promotion.